2,223
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Usefulness of biological markers in the early prediction of corona virus disease-2019 severity

ORCID Icon, , , , , , & show all
Pages 611-618 | Received 09 Jun 2020, Accepted 30 Aug 2020, Published online: 18 Sep 2020
 

Abstract

Coronavirus Disease 2019 is a very fast-spreading infectious disease. Severe forms are marked by a high mortality rate. The objective of this study is to identify routine biomarkers that can serve as early predictors of the disease progression. This is a prospective, single-center, cohort study involving 330 SARS-CoV-2 infected patients who were admitted at the University Hospital of Blida, Algeria in the period between the 27th of March and 22nd of April 2020. The ROC curve was used to evaluate the predictive performance of biomarkers, assessed at admission, in the early warning of progression toward severity. Multivariate logistic regression was used to quantify the independent risk for each marker. After an average follow-up period of 13.9 ± 3.5 days, 143 patients (43.3%) were classified as severe cases. Six biological abnormalities were identified as potential risk markers independently related to the severity: elevated urea nitrogen (>8.0 mmol/L, OR = 9.3 [2.7–31.7], p < .00001), elevated CRP (>42mg/L, OR = 7.5 [2.4–23.3], p = .001), decreased natremia (<133. 6 mmol/L, OR = 6.0 [2.0–17.4], p = .001), decreased albumin (<33.5 g/L, OR = 5.2 [1.7–16.6], p = .003), elevated LDH (>367 IU/L, OR = 4.9 [1.7–14.2], p = .003) and elevated neutrophil to lymphocyte ratio (>7.99, OR = 4.2, [1.4–12.2], p = .009). These easy-to-measure, time-saving and very low-cost parameters have been shown to be effective in the early prediction of the COVID-19 severity. Their use at the early admission stage can improve the risk stratification and management of medical care resources in order to reduce the mortality rate.

Disclosure statement

This research has not supported any specific grants from public, commercial or other not-for-profit funding agencies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.